Apellis upgraded at BofA on launch trajectory for kidney...

2026-01-21 12:15:33 ET More on Apellis Pharmaceuticals Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Apellis Pharmaceuticals: A Good Product That Just Misses The Mark Sobi, Apellis win EU nod for Aspaveli against rare kidney diseases Apellis targets 225 EMPAVELI start forms by year-end amid steady SYFOVRE growth and expanded rare kidney launch Read the full article on Seeking Alpha For further details see: Apellis upgraded at BofA on launch trajectory for kidney disease therapy